Page 123 - 《中国药房》2025年19期

sess Health Care，2003，19（1）：1-7. of inclisiran in treating hypercholesterolemia：a systematic
[ 9 ] SHEA B J，REEVES B C，WELLS G，et al. AMSTAR 2：a review and meta-analysis[J]. Nutr Metab Cardiovasc Dis，
critical appraisal tool for systematic reviews that include 2025，35（5）：103779.
randomised or non-randomised studies of healthcare inter‐ [22] JAWWAD M，RIAZ M，MEHTAB M，et al. Serious ad‐
ventions，or both[J]. BMJ，2017，358：j4008. verse events of inclisiran in patients with hypercholesterole-
[10] HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F， mia，a meta-analysis of ORION trials[J]. Crit Pathw
et al. Consolidated health economic evaluation reporting Cardiol，2024，23（1）：1-11.
Standards 2022 （CHEERS 2022） statement：updated re‐ [23] MIRGHANI H，ALBALAWI B H，ALSHEHRI M S，
porting guidance for health economic evaluations[J]. et al. The efficacy and safety of inclisiran for low-density
Value Health，2022，25（1）：3-9. lipoprotein （LDL） in patients with atherosclerotic cardio‐
[11] National Institute for Health and Care Excellence. Incli‐ vascular disease （ASCVD）：a systematic review of ran‐
siran for treating primary hypercholesterolaemia or mixed domized controlled trials[J]. Cureus，2024，16（9）：e70411.
dyslipidaemia[EB/OL]. （2021-10-06） [2025-05-05]. [24] KHALIL I，RAHMAN M T，HOSSAIN I. The impact of
https：//www.nice.org.uk/guidance/ta733. inclisiran on lipid profiles in adults with hyperlipidemia：a
[12] WANG Y，WANG J S，WANG S M. Comparative effec‐ meta-analysis and meta-regression of randomized con‐
tiveness of inclisiran 100 300，and 500 mg in a population trolled trials[J]. Am J Cardiol，2025，250：20-29.
with hyperlipidemia：a network meta-analysis of rando- [25] MALIHA M，SATISH V，KUMAR S S，et al. The safety
mized controlled trials[J]. Am J Cardiovasc Drugs，2018， profile of inclisiran in patients with dyslipidemia：a sys‐
18（4）：271-282. tematic review and meta-analysis[J]. Healthcare （Basel），
[13] ASBEUTAH A A A，ASBEUTAH S A，ABU-ASSI M A. 2025，13（2）：141.
A meta-analysis of cardiovascular outcomes in patients [26] BASIT J，AHMED M，SINGH P，et al. Safety and effi‐
with hypercholesterolemia treated with inclisiran[J]. Am J cacy of inclisiran in hyperlipidemia：an updated meta-
Cardiol，2020，128：218-219. analysis of randomised controlled trials[J]. Endocrinol
[14] KHAN S A，NAZ A，QAMAR MASOOD M，et al. Meta- Diabetes Metab，2025，8（2）：e70039.
analysis of inclisiran for the treatment of hypercholesterole- [27] KAM N，PERERA K，ZOMER E，et al. Inclisiran as ad‐
mia[J]. Am J Cardiol，2020，134：69-73. junct lipid-lowering therapy for patients with cardiovascu‐
[15] CICERO A F G，FOGACCI F，ZAMBON A，et al. Effi‐ lar disease：a cost-effectiveness analysis[J]. Pharmacoeco‐
cacy and safety of inclisiran：a newly approved FDA drug： nomics，2020，38（9）：1007-1020.
a systematic review and pooled analysis of available clini‐ [28] DESAI N R，CAMPBELL C，ELECTRICWALA B，et al.
cal studies[J]. Am Heart J Plus Cardiol Res Pract，2022， Cost effectiveness of inclisiran in atherosclerotic cardio‐
13：100127. vascular patients with elevated low-density lipoprotein
[16] DUTTA S，SHAH R，SINGHAL S，et al. A systematic re‐ cholesterol despite statin use：a threshold analysis[J]. Am
view and meta-analysis of tolerability，cardiac safety and J Cardiovasc Drugs，2022，22（5）：545-556.
efficacy of inclisiran for the therapy of hyperlipidemic pa‐ [29] ZHOU W J，LIANG Z R，LOU X H，et al. The combina‐
tients[J]. Expert Opin Drug Saf，2024，23（2）：187-198. tion use of inclisiran and statins versus statins alone in the
[17] 俞赟丰，周曼丽，罗晓欣，等 . Inclisiran 治疗高胆固醇血 treatment of dyslipidemia in China’s mainland：a cost-
症的荟萃分析和试验序贯分析[J]. 中国循证心血管医学 effectiveness analysis[J]. Front Pharmacol，2024，15：
杂志，2023，15（9）：1030-1035，1046. 1283922.
[18] LI Y H，XUE K F，HU R，et al. A meta-analysis of the [30] 冯冰，高宁，高胜男，等. 英克司兰注射液治疗动脉粥样
regulation of low-density lipoprotein cholesterol and pro‐ 硬化性心脏病成本效果分析[J]. 医药导报，2025，44（3）：
protein convertase subtilisin-kexin type 9 with inclisiran 466-472.
[J]. Am J Cardiovasc Drugs，2025，25（2）：191-201. [31] LIM Y L，TAN R S，POH K K，et al. Cost-effectiveness
[19] ZHANG S X，SUN L，XU X Y，et al. Efficacy and safety analysis of inclisiran for the treatment of primary hyper‐
of inclisiran versus PCSK9 inhibitor versus statin plus cholesterolemia or mixed dyslipidemia in Singapore[J].
ezetimibe therapy in hyperlipidemia：a systematic review Value Health Reg Issues，2025，47：101067.
and network meta-analysis[J]. BMC Cardiovasc Disord， [32] WANG P P，LIANG L，LI Y M. Cost-effectiveness analy‐
2024，24（1）：629. sis of evolocumab or inclisiran in combination with statins
[20] CHEN Y F，LI S，WANG M J，et al. Inclisiran treatment versus statin monotherapy among patients with ASCVD in
for cardiovascular disease risk reduction：a systematic re‐ China[J]. Appl Health Econ Health Policy，2025，23（5）：
view and meta-analysis[J]. J Coll Physicians Surg Pak， 855-867.
2024，34（9）：1090-1095. （收稿日期：2025-05-14 修回日期：2025-09-01）
[21] CHENG Z L，GAO M L，LIU Y，et al. Safety and efficacy （编辑：刘明伟）

中国药房 2025年第36卷第19期 China Pharmacy 2025 Vol. 36 No. 19 · 2465 ·